48 results about "AIM antigen" patented technology

Embodiments of the present disclosure disclose an antigen-antibody binding conformation optimization method and device based on iterative closest point. A specific embodiment of the method comprises: obtaining a coarse-grained antibody file and a coarse-grained antigen file; performing surface residue extraction on the antigen structure file and the antibody structure file to obtain an antigen surface residue information set and an antibody surface residue information set; generating an antibody binding region residue list; generating an epitope model; performing spatial matching on the antigen surface residue information set and the epitope model to obtain a matched epitope model; generating an antibody docking conformation set; performing local optimization on each antibody docking conformation in the antibody docking conformation set to obtain an optimized antibody conformation set; and screening each optimized antibody conformation in the optimized antibody conformation set to obtain a target antigen-antibody binding conformation. The embodiment can improve the accuracy of the antibody conformation.

The invention provides a double-antibody directionally-coupled FET (Field Effect Transistor) biosensor and a preparation method thereof, and belongs to the technical field of biosensors. The FET biosensor adopts a reference electrode to provide grid voltage, a buffer solution is a conductive electrolyte, the FET biosensor comprises a field effect transistor, a capture antibody and a detection antibody, the field effect transistor is composed of a source electrode, a drain electrode and a channel between the source electrode and the drain electrode, the bottom layer of the channel is an indium oxide thin film layer, the indium oxide thin film layer is modified with amino, and the detection antibody is a detection antibody. An amino-modified channel is obtained; carrying out passivation treatment on the source electrode and the drain electrode by adopting a mercaptan passivator; and cross-linking and fixing the capture antibody and the detection antibody on the channel modified with the amino group through a cross-linking fixing agent to obtain the FET biosensor. The two antibodies are combined according to different epitopes of antigens to form a sandwich structure, and double recognition of the antibodies on target antigens is utilized to enhance antigen capture efficiency and signal enrichment, so that a double-site recognition mode is formed, and low-concentration antigen detection is realized.

This disclosure provides an immunoassay with exceptional sensitivity for detecting a target antigen in a sample. In one disclosure, the capture and detection steps of such an assay utilize recombinant antibodies. The disclosed immunoassay may find specific applications in the detection of HBV antigen.

The invention relates to an antibody design method and device, electronic equipment and a storage medium. Target antigen information and to-be-predicted antibody information correspondingly comprising at least one unknown amino acid are determined; and determining an antigen sequence representation matrix, an antibody sequence representation matrix and at least one feature pair representation matrix according to the target antigen information and the to-be-predicted antibody information, and further determining a corresponding candidate antibody atom structure. And under the condition that the candidate antibody atomic structure is incomplete, determining the candidate antibody atomic structure again according to the to-be-predicted antibody information after updating. And under the condition that the atomic structure of the candidate antibody is completed, determining that the atomic structure of the candidate antibody is the atomic structure of the target antibody matched with the target antigen. The antibody design can be automatically carried out according to the antigen and the to-be-predicted antibody, and the design process is simple and efficient. Meanwhile, antibody design can be carried out for many times in an iterative prediction mode, and an accurate design result is obtained by correcting the antibody structure in the circulation process.

The invention discloses a PD-L1 kit based on proximity ligation and hybrid strand displacement and a detection method, and solves the technical problem of lack of a no-clean, ultra-sensitive and accurate detection method and kit for PD-L1. The kit provided by the invention comprises a monoclonal antibody for capturing a target antigen, an oligonucleotide chain, a detection probe and a hairpin probe. The detection method provided by the invention comprises the following steps: step 1, preparing a monoclonal antibody-DNA conjugate; step 2, establishing an HCR reaction system and amplifying a detection signal through HCR reaction; and step 3, detecting the HCR reaction product in the step 2 through a hairpin probe. The detection method has the advantages of no cleaning, ultra-sensitivity, high accuracy and the like.

The invention provides a low-abundance antigen detection method based on flow-type fluorescent single molecule counting, and belongs to the technical field of biological detection.The method comprises the following steps that after fluorescent encoding microspheres coated with captured antibodies are mixed with a standard sample or a sample to be detected, detection antibodies and nano magnetic beads are added, and the fluorescent encoding microspheres are obtained; or directly adding the nano magnetic beads coated with the detection antibody, reacting to form a double-antibody sandwich compound, separating the compound, and counting by adopting a flow cytometer; and establishing a standard curve of the antigen concentration and the collection number of the fluorescent microspheres, and calculating the concentration of the target antigen in the to-be-detected sample according to the standard curve. The method effectively improves the problem of low sensitivity of a flow fluorescence technology, is low in detection cost and reliable in detection result, and has important significance on low-abundance antigen detection.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

The embodiments of the present disclosure relate to the optimization of an antibody generative model. A method for model training comprises: on the basis of information of a target antigen, using a current antibody generative model to generate a plurality of first antibodies; respectively determining antibody energies of the plurality of first antibodies; on the basis of the antibody energies of the plurality of first antibodies, constructing a plurality of first samples for the antibody generative model, wherein the plurality of first samples comprise at least one positive sample and at least one negative sample, an energy label corresponding to the first antibody in the positive sample indicates that the antibody energy thereof satisfies an energy preference associated with the target antigen, and an energy label corresponding to the first antibody in the negative sample indicates that the antibody energy thereof does not satisfy the energy preference; and using the plurality of first samples to execute fine tuning on the antibody generative model on the basis of an optimization objective, wherein the optimization objective is based on the discrepancy between predicted energy labels of antibodies generated by the fine-tuned antibody generative model and the energy labels of the plurality of first samples.

The invention relates to the technical field of antibodies, in particular to an immune blocker antibody, an anti-rheumatoid factor (RF) antibody or a functional fragment thereof and application of the immune blocker antibody and the anti-rheumatoid factor (RF) antibody. The antibody prepared by the invention can be combined with a target antigen with high specificity, can effectively reduce and even eliminate rheumatoid factor endogenous interference after being added into an immunodetection kit, and is low in cost and high in stability.

Provided herein are lipidated imidazoquinoline compounds and compositions comprising such compounds. The lipidated imidazoquinoline compounds may be used as an adjuvant to enhance to immune response elicited by an antigen of interest. Accordingly, also provided herein are methods for enhancing the immune response of an antigen of interest in a subject, comprising administering to the subject an antigen of interest with a lipidated imidazoquinoline compound described herein in an immunogenic composition, or administering to the subject a composition comprising a lipidated imidazoquinoline compound described herein in combination with (e.g., prior to, concurrently, or subsequently) the administration of an immunogenic composition comprising an antigen of interest to the subject.

The application discloses a digoxin nanobody and a preparation method and application thereof. The amino acid and nucleotide sequences of the digoxin nanobody are shown in SEQ ID NO. 8-9. The antibody has good affinity to a target antigen, and the dissociation constant Kd value is about 73.1 nM, and can be used for digoxin content determination, nucleic acid probe detection and in-vivo digoxin neutralization and detoxification. The antibody has the advantages of small volume, high stability, low cost, low immunogenicity and the like, and has a good application prospect.

Disclosed herein is a universal species-independent method for characterizing antibodies present in a sample that may provide protective immunity against a given pathogen or antigen of interest.

The invention belongs to the technical field of biosensors, and relates to an electrochemical immunosensor for amplifying a detection signal by utilizing a nano-enzymatic electroactive molecule ferrocene-tyramine deposition reaction as well as a preparation method and application of the electrochemical immunosensor. According to the invention, an ultra-sensitive split type biosensor based on 96-well plate and nano-enzyme catalytic electroactive molecule ferrocene-tyramine deposition signal amplification is used, the electroactive molecule ferrocene-tyramine is used as a signal amplification element and is labeled on a signal antibody, and a target antigen is detected through a sandwich immune reaction among a capture antibody probe, a target antigen and the signal antibody. The significant amplification of a current detection signal and the sensitive detection of a target antigen are realized. The sensor and ELISA (enzyme-linked immunosorbent assay) are simultaneously used for detecting the SMP30 antibody level in the serum of a clinical liver cancer patient, the result shows consistency, the recovery rate is 93-104%, and the sensor has great popularization and application value for portable and rapid detection of tumor markers.

The application discloses a universal DC and a preparation method and application thereof, and belongs to the technical field of immune cells. The universal DC is obtained by knocking out HLA-I class genes in original DCs, and does not express HLA-I class molecules. In application, according to HLA-I class molecule typing of target antigen-specific T cells to be obtained, HLA-I class molecules matched with the target antigen-specific T cells are re-expressed in the universal DCs through gene editing, virus or mRNA technology, so that the limitation of HLA-I class molecule cell-specific matching of allogeneic DCs in application is overcome, and the problem of insufficient coverage of single DC HLA-I class molecule typing is solved.

The invention relates to the technical field of antibodies, and discloses an antibody for specifically recognizing porcine pseudorabies virus gE (52-260aa) or an antigen binding fragment thereof and application. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; the antibody can realize specific recognition on gE protein and is used for detecting a target antigen in a sample. The antibody can be used as a core reagent in an immunodetection system, is suitable for laboratory detection and on-site rapid screening of porcine pseudorabies, is beneficial to improving the monitoring efficiency of basic-level and large-scale breeding links, and provides a technical guarantee for early discovery and accurate prevention and control of epidemic situations. Meanwhile, the antibody can also be used as a research tool to be applied to research on gE protein related biological functions and effects of the gE protein in a virus pathopoiesis process, and important support is provided for clarification of virus variation characteristics and optimization of subsequent prevention and control and diagnosis strategies.

The invention relates to a method for improving antigen stability, a cross-linked antigen and application of the cross-linked antigen. The method comprises the following steps: mixing a target antigen with a cross-linking agent to obtain a cross-linked antigen; the cross-linking agent is a hydrophilic cross-linking agent. The cross-linked antigen provided by the invention is relatively good in stability, and relatively good stability can be kept for a long time.

The invention discloses an LSPR (Local Surface Plasmon Resonance) micro-fluidic chip system for rapid typing detection of various virus antigens, and particularly relates to the cross technical field of biomedical engineering, a micro-nano sensing technology, molecular diagnosis and micro-fluidic chip application. According to the present invention, by introducing the PEGylation anti-fouling layer and the BSA sealing treatment, the non-specific adsorption interference is effectively reduced, and compared with the problems that the traditional antigen rapid detection (Ag-RDT) is easily influenced by the virus epitope mutation and the variation is difficult to distinguish, the system can utilize the LSPR peak position red shift difference caused by the combination of different variation antigens and the specific antibody to achieve the precise typing of the multi-variant virus, meanwhile, white light dark field hyperspectral detection is combined with baseline correction, noise filtering and other algorithms, spectral signals can be accurately extracted, and even if interference components such as impurity protein and cell debris exist in a sample, feature signals of a target antigen can still be stably recognized.

The application relates to an antigen binding protein, an antibody or an antibody active fragment obtained by immunizing a camelid with a Sumo tag protein. The application relies on the immune system of the camelid to screen, identify and prepare an antibody specifically recognizing and binding the Sumo tag protein. The obtained antibody has high specificity and can be used for target antigen detection, and has potential clinical diagnosis and treatment values. The antibody provided by the application has simple structure, is easy to be genetically engineered, is easy to be humanized, has high stability, has low mass production cost, and is beneficial to realize large-scale production.

The present invention relates to methods for inhibiting the activity of a cellular immunotherapeutic in a subject who has received or is receiving a therapy with a cellular immunotherapeutic for binding to a target antigen, the method comprising:providing a subject who has received or is receiving a therapy with a cellular immunotherapeutic for binding to a target antigen;administering to the subject, a molecule for binding to the cellular immunotherapeutic, the molecule comprising or consisting of an epitope of the target antigen;wherein the epitope on the molecule competes with an epitope on the target antigen, for binding to the cellular immunotherapeutic and the molecule thereby disrupts the interaction between the cellular immunotherapeutic and the target antigen;thereby inhibiting the activity of the cellular immunotherapeutic in the subject.

The invention discloses an immunodetection probe, a kit and a detection method based on proximity ligation and nucleic acid amplification in the technical field of biological detection. The immunodetection probe comprises an antibody modified probe A, an antibody modified probe B and a splint probe, the antibody modification probe A comprises a first antibody and a first DNA chain, the antibody modification probe B comprises a second antibody and a second DNA chain, and the splint probe sequentially comprises a front end chain, a primer complementary chain and a rear end chain from the 5'end to the 3 'end; the first antibody and the second antibody can be specifically combined with different epitopes of the same target antigen to form a sandwich compound. By designing a double-hairpin closed probe with a synergistic effect, non-specific hybridization and connection are greatly inhibited from a molecular stress level by utilizing self-closing of a hairpin structure of the probe in an uncombined state and a specific open-loop mechanism under adjacent triggering, so that a background signal is remarkably reduced; the near-quantitative and high-efficiency formation of the circular DNA template is realized, and the uniformity and stability of signal generation are guaranteed.

The present disclosure provides CyCAT halfbody molecules and complementary pairs of such halfbody molecules which are capable of associating with each other on the surface of a cell expressing two target antigens of interest. The thus on-cell and on target formed trispecific heterodimeric antibody molecules are capable of engaging and stimulating cytotoxic T-cells for tumor cell destruction. The present disclosure further provides halfbody molecules having sterically occluding moieties attached thereto which reduce heterodimer formation of such halfbodies in the presence of only one or absence of both target antigens of interest.

Embodiments of the present disclosure relate to optimization of antibody generation models. The method for model training comprises the following steps: generating a plurality of first antibodies by using a current antibody generation model based on information of a target antigen; respectively determining respective antibody energy of the plurality of first antibodies; based on the antibody energy of the plurality of first antibodies, constructing a plurality of first samples for an antibody generation model, the plurality of first samples including at least one positive sample and at least one negative sample, the energy tag corresponding to the first antibody in the positive sample indicating that the antibody energy thereof satisfies the energy preference associated with the target antigen, and the energy tag corresponding to the second antibody in the negative sample indicating that the antibody energy thereof satisfies the energy preference associated with the target antigen; the energy label corresponding to the first antibody in the negative sample indicates that the antibody energy does not meet the energy preference; and performing fine tuning on the antibody generation model according to an optimization target using the plurality of first samples, the optimization target being based on a difference between a predicted energy tag of an antibody generated by the fine-tuned antibody generation model and an energy tag between the plurality of first samples.

A method of quantitatively analyzing an antigen includes a step of mixing an assay sample comprising a target antigen, magnetic particles on which a first antibody subjected to an antigen-antibody reaction with the target antigen is immobilized, and beads on which a second antibody different from the first antibody is immobilized; a step of adding dropwise the mixed assay sample to a microchip for quantitatively analyzing an antigen; a step of introducing the microchip into a digital inline microscope-based detector comprising a magnetic force applicator and applying magnetism to the magnetic force applicator; and a step of detecting the beads using images acquired in the detector to count the number of the target antigens.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic bacterial DNA nanomicelle, its preparation method, and its applications. By mimicking the structural and functional characteristics formed when microorganisms infect a host, exogenous nucleic acid stimulation signals and oxidative stress regulation functions are integrated into a single nanostructure. A micellar nanostructure is designed, comprising a complex of oligonucleotides containing CpG motifs and ferrocene groups, which is formed through self-assembly in solution. This nanomicelle can significantly promote the proliferation or differentiation of dendritic cells, improve their maturity, and enhance their immune activation capacity; by enhancing the cross-presentation capacity of dendritic cells to target antigens, it effectively promotes cytotoxic CD8+. + T-cell immune responses; it can also enhance the body's cellular immune response by inducing the activation and proliferation of antigen-specific cells. These DNA nanomicelles have significant clinical application value in areas such as vaccine adjuvants, tumor immunotherapy, and immune regulation.

The present invention provides a novel CAR design containing a modified CD3ζ chain, and cells containing genetically modified immune-responsive cells (e.g., T cells, NK cells, or CTL cells) containing the CAR. [Solution] This disclosure provides a chimeric antigen receptor (CAR) that binds to an antigen of interest. The CAR can bind to a tumor antigen or a pathogen antigen. In certain non-limiting embodiments, the CAR comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide.

Disclosed in the present application are a marker combination for screening target antigen-specific T cells and the use thereof. The present application provides a marker combination for efficiently screening virus antigen / tumor neoantigen-specific T cells, and provides a method for in-vitro screening target antigen-specific T cells on the basis of the marker combination. Upon verification, 90% or more of the CD8+T cells screened by the method are T cells specifically targeting the virus antigen / tumor neoantigens. Compared with a previous CD137 marker used alone, the success rate of screening is significantly improved.

The present invention provides a chimeric antigen receptor (CAR) targeting BCMA and its anticancer use, wherein the chimeric antigen receptor comprises an extracellular region, a transmembrane region and an intracellular region, wherein the extracellular region comprises a signal peptide, an anti BCMA scFv and a hinge region, wherein the intracellular region comprises a co-stimulatory factor and a CD3ζ signal domain, and wherein the anti BCMA scFv comprises a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 1 and a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 2. The BCMA-targeted antigen binding domain has a unique amino acid structure and can specifically bind to the target antigen, and the CAR-T cells can effectively inhibit tumor cell proliferation in vivo and in vitro, and prolong the survival of experimental animals.

The invention discloses a kit for detecting veterinary drug residues in meat food, the kit comprises a test strip and a detection agent, the detection agent comprises a buffer solution and a signal probe, and the signal probe is a colloidal gold labeled monoclonal antibody of an anti-target antigen; the colloidal gold is modified by facultative ion polypeptide; the facultative ionic polypeptide is formed by combining acidic amino acid and basic amino acid and has good anti-pollution performance, so that the signal probe has strong hydrophilic property, a firm hydration layer can be formed on the surface, the effect of inhibiting adhesion and interference of matrix components is achieved, the stability of the detection process can be improved, and the detection sensitivity is improved. The non-specific adhesion of a complex matrix on the surface of the colloidal gold can be eliminated, so that the interference of the complex matrix on the detection process is inhibited; the detection line of the test strip is coated with a target antigen-BSA, the quality control line is coated with a cationic polymer, the kit is used for detecting veterinary drug residues in meat food, the cost is low, operation is easy and convenient, detection is efficient, and the kit can be used for on-site detection.

The present invention provides a method of quantitatively analyzing an antigen, the method comprising: a step of mixing an assay sample comprising a target antigen, magnetic particles on which a first antibody subjected to an antigen-antibody reaction with the target antigen is immobilized, and beads on which a second antibody different from the first antibody is immobilized; a step of adding dropwise the mixed assay sample to a microchip for quantitatively analyzing an antigen; a step of introducing the microchip into a digital inline microscope-based detector comprising a magnetic force applicator and applying magnetism to the magnetic force applicator; and a step of detecting the beads using images acquired in the detector to count the number of the target antigens.

Disclosed herein are binding polypeptides that bind to asialoglycoprotein receptor 1 (ASGR1), and methods of use thereof for inducing immune tolerance against antigens of interest, for example, for treating, ameliorating, inhibiting, or preventing disease or disorders associated with unwanted immune response against the antigens of interest, such as autoimmune diseases.